Bilateral pelvic lymph node dissection for Chinese patients with penile cancer: a multicenter collaboration study

Li, Zai Shang; Deng, Congying; Yao, Kai; Tang, Yong; Liu, Nan; Chen, Peng; Wang, Bin; Li, Xiang; Chen, Xiaofeng; Hong, Lan; Mi, Qi Wu; Lei, Yong; Zhao, Qi; Zhao, Pei; Li, Xue Ying; Chen, Jie Ping; Zhou, Qiang; Qin, Zi Ke; Liu, Zhuo Wei; Li, Yong Hong; Ye, Yun Lin; Tu, Hua; Zou, Zi Jun; Bi, Xing; Feng, Yu; Xiao, Ying; Li, Jing; Lin, Xiang; Wei, Liang; Han, Hui; Zhou, Fang

doi:10.1007/s00432-016-2292-3

Cited by 14 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All 57 patients with PLNM had inguinal LNM. As opposed to other studies where crossover was not found [9,10,12], two patients with unilateral inguinal LNM had bilateral PLNM, suggesting crossover from inguinal nodes to contralateral pelvic nodes. Lopes et al similarly documented metastasis to the pelvic nodes with no inguinal involvement [15].…”

Section: Lymph Node Mappingcontrasting

confidence: 99%

“…Chipollini et al performed PLND in 198 chemonaïve patients, of which 106 (53.5%) were bilateral dissections. The median number of lymph nodes (LN) and the median number of positive LN were 13 (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)) and 2 (1-4), respectively. The survival analysis revealed that patients with a lymph node yield of ≥9 LN had better 5-year disease-specific survival (DSS) (64.2% vs. 47.2%), overall survival (OS) (60.3% vs. 39.8%), and recurrencefree survival (RFS) (60.3% vs. 43.2%).…”

Section: Pelvic Lymph Node Yield Impacts Survivalmentioning

confidence: 99%

“…However, propensity score matching among pN2 patients showed higher DSS in patients who underwent PLND compared to those who did not (83.3% and 83.3% vs. 69.0% and 50.2%, p = 0.030). Based on their analyses, a significant benefit was found for a subset of pN2 cases, while pN3 patients may not benefit from bilateral PLND [12].…”

Section: Bilateral Plnd Vs No-plndmentioning

confidence: 99%

See 2 more Smart Citations

Is There an Oncological Benefit of Performing Bilateral Pelvic Lymph Node Dissection in Patients with Penile Cancer and Inguinal Lymph Node Metastasis?

Suarez-Ibarrola

Basulto-Martínez

Sigle

et al. 2021

JCM

View full text Add to dashboard Cite

We aim to review the literature for studies investigating the oncological outcomes of patients with penile cancer (PC) undergoing bilateral pelvic lymph node dissection (PLND) in the presence of inguinal lymph node metastasis (LNM) who are at risk of harboring pelvic metastasis. A search of English language literature was performed using the PubMed-MEDLINE database up to 3 December 2020 to identify articles addressing bilateral PLND in PC patients. Eight articles investigating bilateral PLND met our inclusion criteria. Patients with pelvic LNM have a dismal prognosis and, therefore, PLND has an important role in both the staging and treatment of PC patients. Ipsilateral PLND is recommended in the presence of ≥2 positive inguinal nodes and/or extranodal extension (ENE). Significant survival improvements were observed with a higher pelvic lymph node yield, in patients with pN2 disease, and in men treated with bilateral PLND as opposed to ipsilateral PLND. Nevertheless, the role of bilateral PLND for unilateral inguinal LNM remains unclear. Although the EAU guidelines state that pelvic nodal disease does not occur without ipsilateral inguinal LNM, metastatic spread from one inguinal side to the contralateral pelvic side has been reported in a number of studies. Further studies are needed to clarify the disseminative pattern of LNM, in order to establish PLND templates according to patients’ risk profiles and to investigate the benefit of performing bilateral PLND for unilateral inguinal disease.

show abstract

Section: Lymph Node Mappingcontrasting

confidence: 99%

Section: Pelvic Lymph Node Yield Impacts Survivalmentioning

confidence: 99%

See 1 more Smart Citation

Is There an Oncological Benefit of Performing Bilateral Pelvic Lymph Node Dissection in Patients with Penile Cancer and Inguinal Lymph Node Metastasis?

Suarez-Ibarrola

Basulto-Martínez

Sigle

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…[3][4][5] The main treatment for PSCC is currently a partial or radical penectomy with or without bilateral inguinal Dovepress Dovepress 2984 Zhou et al lymphadenectomy, along with radiation, chemotherapy, and targeted therapy. 1,[6][7][8][9] Some classical serum biomarkers (such as CEA, AFP, PSA, and CA-199) are clinically useful in many cancers [10][11][12] ; however, they are not suitable in penile cancer. Serum C-reactive protein (CRP) and squamous cell carcinoma antigen (SCC-Ag) were reported to be prognostic markers in PSCC.…”

Section: Introductionmentioning

confidence: 99%

Elevated serum LAMC2 is associated with lymph node metastasis and predicts poor prognosis in penile squamous cell carcinoma

Zhou

Deng

Chen

et al. 2018

CMAR

Self Cite

View full text Add to dashboard Cite

PurposeMolecular biomarkers, especially serologic factors, have been widely applied in cancer diagnosis and patient follow-up. However, there are few valuable prognostic factors in penile squamous cell carcinoma (PSCC). Here, the authors investigated whether laminin gamma 2 (LAMC2) expression, especially serum LAMC2 (sLAMC2) level, was a suitable prognostic factor that could aid in the prediction of survival in PSCC.Patients and methodsThis study included 114 PSCC patients. Reverse transcription-quantitative polymerase chain reaction, Western blotting, and immunohistochemistry were performed to detect LAMC2 expression; enzyme-linked immunosorbent assays were used to test sLAMC2 concentration; and a Transwell assay and an in vivo experiment in nude mice were used to test PSCC cell migration, invasion, and metastasis. The chi-squared test was used to analyze the association between LAMC2 level and clinical parameters, the Cox proportional hazards regression model was used to evaluate the hazard ratio for death, and Kaplan–Meier analysis with a log-rank test was used for the survival analysis.ResultsLAMC2 was overexpressed in PSCC tissues, and the LAMC2 expression level was higher in metastatic lymph node (LN) tissues than in primary cancer tissues; moreover, the LAMC2 levels in primary cancer tissues and sLAMC2 were higher in patients with LN metastasis than in those without LN metastasis. Upregulated LAMC2 facilitated the migration, invasion, and epithelial-to-mesenchymal transition of PSCC cells in vitro and promoted LN metastasis of PSCC cells in nude mice. Elevated LAMC2 levels were strongly correlated with advanced clinicopathologic parameters, especially LN metastasis, in PSCC patients and predicted shorter disease-specific survival. The predictive value of sLAMC2 is superior to that of C-reactive protein and squamous cell carcinoma antigen previously reported in PSCC patients, and a stratification analysis revealed that the level of sLAMC2 had a higher predictive value for disease-specific survival in early penile cancer (especially at the N0/X stage) than in later-stage penile cancer.ConclusionThese findings suggest that sLAMC2 is a potential serologic prognostic marker in PSCC and could aid in risk stratification in early-stage PSCC patients.

show abstract

“…Another recent contemporary series of only modified template ILND (cases from 2002 to 2011) cited a lower complication rate of 10% with only a quarter of these complications being major ( 11 ). The concern persists, however, that one must not sacrifice lymph node yield for morbidity as many studies have demonstrated that greater lymph node yield and lower lymph node density portend survival benefit ( 13 , 14 ).…”

Section: Introductionmentioning

confidence: 99%

Robotic inguinal lymphadenectomy for penile cancer: the why, how, and what

Elsamra¹,

Poch²

2017

Transl. Androl. Urol.

View full text Add to dashboard Cite

Squamous cell carcinoma of the penis (SCC-P) demonstrates a reliable pattern of spread to the lymph nodes of the groin. High grade and higher stage (pT1b or greater) SCC-P demonstrate a higher propensity for metastasis to the inguinal lymph nodes. Further, lymphadenopathy progresses in a predictable fashion, from superficial inguinal lymph nodes to deep inguinal lymph nodes to pelvic lymph nodes, with limited survival noted for those patients with progression to pelvic lymph nodes. Fortunately, inguinal lymphadenectomy can provide cure and improvement in RFS for SCC-P. Unfortunately open inguinal lymphadenectomy is associated with significant morbidity. Perhaps owing to this morbidity, inguinal lymphadenectomy is underperformed in the US. In other words, urologists only offer inguinal lymphadenectomy for high risk SCC-P in only a minority of cases and even when performed, lymph node yield is often unsatisfactory (less than 8 nodes per groin). Recently, a laparoendoscopic inguinal lymphadenectomy has been developed as a new approach to offer potentially curative lymph node resection while minimizing morbidity. The robotic platform has since been adapted for this approach and several reports demonstrate significant improvements in morbidity while maintaining oncologic equivalency. This review highlights the rationale for inguinal lymphadenectomy, inguinal lymph node anatomy, and technical considerations and outcomes of laparoscopic and robotic inguinal lymphadenectomy.

show abstract

Bilateral pelvic lymph node dissection for Chinese patients with penile cancer: a multicenter collaboration study

Abstract: Bilateral PLND may improve survival in pN2 patients. Men with pN3 may not benefit from bilateral PLND.

Cited by 14 publications

References 25 publications

Is There an Oncological Benefit of Performing Bilateral Pelvic Lymph Node Dissection in Patients with Penile Cancer and Inguinal Lymph Node Metastasis?

Is There an Oncological Benefit of Performing Bilateral Pelvic Lymph Node Dissection in Patients with Penile Cancer and Inguinal Lymph Node Metastasis?

Elevated serum LAMC2 is associated with lymph node metastasis and predicts poor prognosis in penile squamous cell carcinoma

Robotic inguinal lymphadenectomy for penile cancer: the why, how, and what

Contact Info

Product

Resources

About